Gale M J, Korth M J, Katze M G
Regional Primate Research Center and Department of Microbiology, School of Medicine, University of Washington, Seattle 98195-7542, USA.
Clin Diagn Virol. 1998 Jul 15;10(2-3):157-62. doi: 10.1016/s0928-0197(98)00034-8.
Chronic infection with hepatitis C virus (HCV) is associated with progressive liver damage, including the development of cirrhosis and hepatocellular carcinoma, and HCV is a leading cause of liver dysfunction worldwide. The current therapy for chronic HCV infection, interferon-alpha (IFN), is effective in a minority of HCV-infected patients. Several studies have demonstrated a correlation between therapeutic outcome and the amino acid sequence of a small region of the HCV non-structural 5A (NS5A) gene product. It has been suggested that this region, termed the interferon sensitivity-determining region (ISDR), may mediate IFN resistance by directly interacting with one or more cellular proteins associated with the IFN-mediated antiviral response.
In an attempt to define the molecular mechanism by which the NS5A protein and the ISDR might contribute to HCV resistance to IFN, we examined whether NS5A could regulate the IFN-induced protein kinase, PKR, a primary mediator of the IFN-induced antiviral response.
Multiple approaches, including in vitro assays using recombinant proteins, the transfection of recombinant clones into cultured cells, and in vivo studies in yeast, were used to examine the interaction of NS5A with PKR, as well as the functional significance of the interaction. An ISDR deletion mutant was prepared to evaluate the importance of the ISDR in mediating the NS5A-PKR interaction and the requirement of this region for PKR inhibition.
NS5A repressed PKR activity through a direct interaction with the protein kinase catalytic domain. Both PKR repression and interaction required the presence of the ISDR.
Inactivation of PKR may be one mechanism by which HCV avoids the antiviral effects of IFN. Thus,therapeutic strategies designed to block the NS5A-PKR interaction may increase the efficacy of IFN therapy in HCV-infected individuals.
丙型肝炎病毒(HCV)慢性感染与进行性肝损伤相关,包括肝硬化和肝细胞癌的发生,并且HCV是全球肝功能障碍的主要原因。目前用于慢性HCV感染的治疗方法,即α干扰素(IFN),仅对少数HCV感染患者有效。多项研究表明治疗结果与HCV非结构5A(NS5A)基因产物一小区域的氨基酸序列之间存在相关性。有人提出,这个被称为干扰素敏感性决定区(ISDR)的区域可能通过与一种或多种与IFN介导的抗病毒反应相关的细胞蛋白直接相互作用来介导IFN耐药性。
为了确定NS5A蛋白和ISDR可能导致HCV对IFN耐药的分子机制,我们研究了NS5A是否能调节IFN诱导的蛋白激酶PKR,PKR是IFN诱导的抗病毒反应的主要介质。
采用多种方法,包括使用重组蛋白的体外试验、将重组克隆转染到培养细胞中以及在酵母中进行体内研究,来检测NS5A与PKR的相互作用以及这种相互作用的功能意义。制备了一个ISDR缺失突变体,以评估ISDR在介导NS5A-PKR相互作用中的重要性以及该区域对PKR抑制的必要性。
NS5A通过与蛋白激酶催化结构域直接相互作用来抑制PKR活性。PKR的抑制和相互作用都需要ISDR的存在。
PKR失活可能是HCV逃避IFN抗病毒作用的一种机制。因此,旨在阻断NS5A-PKR相互作用的治疗策略可能会提高IFN治疗HCV感染个体的疗效。